• Ring The Bell
  • Posts
  • 📈 How Inflation Fears Are Splitting Consumer Optimism

📈 How Inflation Fears Are Splitting Consumer Optimism

Plus a handful of compelling "speakeasy" stocks, and more

You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

Back to Monday! Consumer sentiment hit a seven-month high, driven by strong buying conditions, but inflation fears sparked partisan divides. Markets rose on optimism, with rate cuts now widely expected. Here’s how to navigate the shifting economic landscape. Also, take a look at five stocks that are quietly getting the nod.

Plus, if you’re interested in boosting your options performance with AI, check out our sponsor.

MARKET RECAP

Last Week: The S&P 500 and Nasdaq hit new highs as jobs data showed economic resilience without fueling inflation fears. Bond yields fell to six-week lows, while energy lagged and tech outperformed. Oil stayed steady as OPEC delayed production hikes.

On Our Radar: Some important economic data will be released next week, beginning with wholesale inventories later this morning. On the earnings front, tech specialist C3.ai will disclose its results after the closing bell today.

TOP STORY

Consumer sentiment surged to a seven-month high as buyers moved to beat future price hikes, but rising inflation fears divided Democrats and Republicans. Markets climbed on optimism and growing rate-cut expectations.

SPONSORED CONTENT

Options trading is all about timing and direction.  

Choose the right Options play at the right time, and the rewards can be significant. 

Learn FREE: 

  • How A.I. predicts market movements over the next few days

  • Uncover Hidden Trends: Learn how to identify the best trends before they hit the mainstream. 

  • Scanning techniques to find explosive trade opportunities

Join us LIVE and study how A.I. can help you stay ahead of the curve in trading.

FIVE ZINGERS

Punching Back: After incurring weather-related disruptions in October, November’s jobs report witnessed a stronger-than-expected rebound, along with a slight bump in wage growth. Find out which sectors are currently on an uptrend.

Security Detail: Even before the shocking killing of UnitedHealthcare CEO Brian Thompson, companies boosted their security budgets over recent years. These are the enterprises that have spent the most on executive protection.

Borrowed Time: On Friday, video-sharing platform TikTok lost its bid to block a law that may result in its ban in the U.S. These are the companies that saw the biggest boost in the market following the news.

Furry Fortune: While Petco Health and Wellness has been a disappointing investment since its debut, recent momentum possibly warrants a closer look. Here’s why analysts are warming to WOOF stock.

High Finance: After gaining prominence from the meme-stock phase, Wall Street analysts have warmed to Robinhood. Read why Goldman Sachs analyst James Yaro reiterated an Overweight rating on HOOD stock.

SPECIAL OFFER

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

On Friday, Benzinga Edge members received a list of five of these up-and-coming stocks. As a valued Ring the Bell reader, today you’re getting a sneak peek at one of them:

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.

Protara Therapeutics: Protara shares soared on the week after the company reported Phase 2 results from its ADVANCED-2 trial. The trial, which is for TARA-002 which targets invasive bladder cancer, showed a complete response for many patients.

The company reported the results at the 25th Annual Meeting of the Society of Urologic Oncology. Protara will report the data from 12-month evaluable patients for the trial in mid-2025.

To keep reading, and get the other four Whisper Index stocks, sign up for Benzinga Edge here.

SPONSORED CONTENT

Join two veteran traders December 15th for their complete system: Find perfect entries, manage risk, and catch potential +1,452% winners others miss. Click here to secure your free spot now.

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.

Cannabis Daily: A must-read daily briefing for cannabis investors, operators, and enthusiasts. Join our list of industry veterans to jump start your morning. Subscribe here.

Real Estate Weekly: Ready to elevate your real estate game? This weekly newsletter provides actionable insights whether you are investing in REITs, owning property, or delving into the fast-growing world of fractional real estate. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.